Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Enlivex Therapeutics Ltd (ENLV)

Enlivex Therapeutics Ltd (ENLV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Enlivex Therapeutics Ltd 14 Einstein Street Ness Ziona L3 7403618 ISR

www.enlivex.com Employees: 36 P: 972-2620-8072 F: 972-262-0807

Sector:

Medical

INDUSTRY GROUPING:

Medical - Drugs

Description:

Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing.

Key Statistics

Overview:

Market Capitalization, $K 221,667
Enterprise Value, $K 218,367
Shares Outstanding, K 237,382
Float, K 208,232
% Float 87.72%
Short Interest, K 233
Short Float 0.10%
Days to Cover 1.00
Short Volume Ratio 0.15
% of Insider Shareholders 12.28%
% of Institutional Shareholders 1.02%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -15,010 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -2,210 K
EBIT, $ -14,800 K
EBITDA, $ -14,250 K

Growth:

1-Year Return -18.26%
3-Year Return -77.50%
5-Year Return -92.25%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 34.23%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.09 on 11/14/25
Next Earnings Date 03/30/26
Earnings Per Share ttm -0.55
EPS Growth vs. Prev Qtr -12.50%
EPS Growth vs. Prev Year 25.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-8 on 03/06/19

ENLV Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -62.91%
Return-on-Assets % -53.33%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 1.34
Book Value/Share 0.72
Interest Coverage -1.85
60-Month Beta 1.52
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar